USP18 and colorectal cancer: As shown in Figure 2I,J, compared with patients in the USP18 low-expression group, patients in the USP18 high-expressing colorectal cancer group had significantly longer overall survival (OS) (HR = 0.8, p = 0.034) and prolonged progression-free survival (PFS), but these differences were not statistically significant (HR = 0.7, p = 0.061).